Literature DB >> 33757566

Long non-coding RNA SPRY4-IT1 as a promising indicator for three field lymph-node dissection of thoracic esophageal carcinoma.

Peng Qie1, Qifan Yin2, Xuejiao Xun2, Yongbin Song2, Shaohui Zhou2, Huining Liu2, Junpeng Feng3, Ziqiang Tian4,5.   

Abstract

BACKGROUND: Esophageal squamous cell carcinoma(ESCC) is one of the most common tumors worldwide. Esophagectomy with three-field lymph node dissection(3FLND) is the radical surgical procedure for esophageal cancer. However, 3FLND is not widely used due to it's higher mortality rate and higher incidence of postoperative complications. There is an urgent need to identify novel biomarkers that can guide the most proper lymph-node dissection in esophageal cancer patients.
METHOD: Ninety-two patients with thoracic ESCC undergoing 3FLND were enrolled into our study from the Department of Thoracic Surgery of the Fourth Hospital affiliated to the Hebei Medical University and Hebei General Hospital between Jun 2011 and Dec 2015. Retrospectively collected data from these 92 patients was used to explore the relationship between the lymph-node metastasis、recurrence and the SPRY4-IT1 expression level and to determine whether 3FLND should be performed in patients with thoracic ESCC.
RESULTS: The findings revealed that the SPRY4-IT1 expression was significantly higher in esophageal cancer tissues than in adjacent noncancerous tissues. (P < 0.01). Furthermore, the high expression of SPRY4-IT1 was significantly correlated with tumor differentiation (P = 0.029), T classification (P = 0.013), lymph node metastasis(P = 0.022) and pathological stage (P = 0.001). The increased expression of SPRY4-IT1 was associated with a higher risk of cervical and superior mediastinal lymph-node metastasis(P = 0.039).However, no significant association was observed between the risk of cervical and superior mediastinal lymph-node recurrence and the SPRY4-IT1 expression level in the thoracic ESCC patients performed 3FLND(P = 0.509).
CONCLUSIONS: Our data support the assumption that the high expression of SPRY4-IT1 is associated with a high risk of lymph node metastasis and it has potential application as a indicator for guiding on three-field lymph node dissection in patients with thoracic ESCC. Randomized controlled trials with a large cohort of patients will be needed to confirm this conclusion in the future.

Entities:  

Keywords:  Biomarker; Esophageal carcinoma; SPRY4-IT1; Three field lymph-node dissection

Mesh:

Substances:

Year:  2021        PMID: 33757566      PMCID: PMC7988958          DOI: 10.1186/s13019-021-01433-x

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  26 in total

1.  Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.

Authors:  Xiao-Lei Zhao; Zhen-Hua Zhao; Wen-Chao Xu; Jun-Qing Hou; Xin-Yi Du
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer.

Authors:  Harushi Udagawa; Masaki Ueno; Hisashi Shinohara; Shusuke Haruta; Sachiko Kaida; Masatoshi Nakagawa; Masahiko Tsurumaru
Journal:  J Surg Oncol       Date:  2012-04-13       Impact factor: 3.454

Review 3.  Three-field lymph node dissection in treating the esophageal cancer.

Authors:  Qi-Xin Shang; Long-Qi Chen; Wei-Peng Hu; Han-Yu Deng; Yong Yuan; Jie Cai
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  Cervical lymph node dissection for clinically submucosal carcinoma of the thoracic esophagus.

Authors:  Shin-ichi Kosugi; Yoshihiko Kawaguchi; Tatsuo Kanda; Takashi Ishikawa; Kaoru Sakamoto; Hidenori Akaike; Hideki Fujii; Toshifumi Wakai
Journal:  Ann Surg Oncol       Date:  2013-07-27       Impact factor: 5.344

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

6.  Patterns of lymphatic spread in thoracic esophageal cancer.

Authors:  T Nishimaki; O Tanaka; T Suzuki; K Aizawa; K Hatakeyama; T Muto
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

7.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy.

Authors:  H Fujita; T Kakegawa; H Yamana; I Shima; Y Toh; Y Tomita; T Fujii; K Yamasaki; K Higaki; T Noake
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

8.  Up-Regulated Expression of SPRY4-IT1 Predicts Poor Prognosis in Colorectal Cancer.

Authors:  Wenlong Tan; Zi-Zheng Song; Qunfang Xu; Xinyan Qu; Zhen Li; Yu Wang; Qun Yu; Shengqi Wang
Journal:  Med Sci Monit       Date:  2017-01-18

9.  EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.

Authors:  M Sun; X-H Liu; K-H Lu; F-Q Nie; R Xia; R Kong; J-S Yang; T-P Xu; Y-W Liu; Y-F Zou; B-B Lu; R Yin; E-B Zhang; L Xu; W De; Z-X Wang
Journal:  Cell Death Dis       Date:  2014-06-26       Impact factor: 8.469

10.  Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.

Authors:  Chi Han Li; Yangchao Chen
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

View more
  2 in total

Review 1.  A Review on the Role of SPRY4-IT1 in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Mohammad Taheri; Seyedpouzhia Shojaei
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 2.  Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.

Authors:  Aditi Kulkarni; Sharan Gayathrinathan; Soumya Nair; Anamika Basu; Taslim A Al-Hilal; Sourav Roy
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.